Abstract The antiapoptotic factor Livin has been considered critical for tumor progression and poor prognosis for variant types of tumors. However, there are only limited reports regarding its expression and biological functions in colon cancer. Here, we examined Livin expression in four colon cancer cell lines (HCT116, RKO, KM12C, and SW620) in the presence or absence of cisplatin that was used as a model reagent. We found the different response to cisplatin was related to endogenous Livin expression level. From among a panel of apoptosis-related factors (p53, Bcl-2, Bcl-XL, BAX, and survivin), the expression of Livin was upregulated after cisplatin treatment in a dose-dependent manner. Both immunocytochemistry and nuclear cytoplasmic fractionation indicated Livin remained in the cytoplasm after treatment with cisplatin. In an attempt to explore the mechanism, we found the elevated expression of Livin was not due to the decreased degradation by proteosome but was enhanced at the mRNA level. Besides, cisplatin treatment activated the mammalian target of rapamycin (mTOR) pathway as shown by increased phosphorylation of Akt1, mTOR, S6K, and 4E-BP1, together with the elevated Livin. The PI3K inhibitor LY294002 inhibited both the phosphorylation of mTOR and upregulation of Livin. The stable overexpression of Livin inhibited the activation of caspase-3 and led to resistance to cisplatin, while the knockdown of Livin by siRNA rendered colon cancer cells more sensitive to cisplatin. Our study, along with others, highlighted the potential of Livin for cancer therapy in colon cancer.
Introduction
Key mediators in apoptosis regulation are of intense biological interest. Inhibitor of Apoptosis (IAP) family of proteins was discovered as endogenous caspase inhibitors of apoptosis induced by a variety of stimuli [1] . Livin has been identified as a member of the IAP family [2] [3] [4] . Its expression spectrum includes melanoma, leukemias, bladder cancer, breast cancer, cervical cancer, nasopharyngeal cancer, and lung cancer [5] [6] [7] [8] . Interestingly, its expression is hardly detectable or present at substantially lower levels in the normal tissue [9] . Two splicing variants have been identified (designated α-and β-isoforms) for Livin, which are almost identical except for a 54-bp truncation in exon 6 [10] . The overexpression of both isoforms blocks apoptosis induced by TNF-α and anti-CD95 antibody. It was proposed that Livin could inhibit apoptosis by binding and suppressing downstream caspases through its Baculoviral IAP Repeat domain [3, 4] , but this is still controversial [11] . Another report awaiting further confirmation argued that inhibition of apoptosis by Livin might involve the TAK1/JNK1 pathway [12] . Also, Livin could bind and degrade Second Mitochondrial Activator of Caspases (SMAC) through its Cterminal RING zinc-finger (RING) domain [13] . This may further contribute to its antiapoptotic function.
Colorectal cancer (CRC) is one of the leading causes of cancer death in Western countries [14, 15] . Platinum-based compounds represent one of the main therapeutic options for solid tumors. Cisplatin (cis-diamminedichloroplatinum) is widely used as a DNA-damaging drug in this category. It interacts with DNA, resulting in the formation of DNA adducts, primarily intrastrand crosslinks [16] . Subsequently, it induces DNA damage recognition proteins to signal to downstream effectors such as p53, resulting in cell cycle arrest and apoptosis. To date, little is know on the Livin expression profile in Colorectal cancer (CRC) except for preliminary reports [17] [18] [19] [20] [21] . Neither is the relationship between Livin expression and cisplatin sensitivity in Colorectal cancer (CRC) known. In this study, we attempted to clarify the mechanisms behind the effects of Livin on cisplatin treatment in Colorectal cancer (CRC) cells with respect to apoptosis.
Materials and methods

Plasmid constructions
The full-length cDNA of Livin was amplified from total RNA isolated from fresh tissue of a metastatic malignant melanoma by reverse transcript polymerase chain reaction (RT-PCR) with the following primers: 5′-AATAGATCT-CATGGGACCTAAAGACAGTGCC-3′ (sense) and 5′-AATGGATCCGGACAGGAAGGTGCG-3′ (antisense). When the product of the expected size was obtained, it was inserted into UA cloning vector pDrive (Qiagen, Valencia, CA, USA) and then subcloned into pcDNA 3.1 (Invitrogen, Carlsbad, CA, USA) to obtain the expression plasmid. The construct was verified by sequencing.
Reagents and cells
Cytotoxic drug cisplatin and oxaliplatin, caspase-3 inhibitor z-DEVD-fmk, the colorimetric caspase-3 substrate z-DEVD-pNA, proteosome inhibitor MG-132, protein synthesis inhibitor actinomycin D, antibiotic Geneticin, and dual inhibitor for PI3K and mammalian target of rapamycin (mTOR) LY294002 were all purchased from SigmaAldrich (Stockholm, Sweden). Stock preparation of the reagents was stored at −20°C until use. The working concentration of LY294002 was 20 μM.
Human colon cancer cell lines HCT-116, RKO, SW620, and human embryonic kidney (HEK) cells were from the American Type Culture Collection (ATCC). Human colon cancer cell line KM12C was a kind gift from Professor IJ Fidler (Anderson Cancer Center, TX, USA). All cells were maintained in Minimal Essential Medium (Sigma-Aldrich) supplemented with 10 % fetal bovine serum (FBS) (Gibco, Invitrogen, Carlsbad, CA, USA), 1.5 mM L-glutamine (Gibco), and 1× PEST (Gibco) at 37°C in a 5 % CO 2 incubator except for HCT-116, which was cultivated in McCoy's 5A medium (Sigma-Aldrich). Mycoplasma contamination was excluded for all the cells by using a commercially available PCR kit (PromoKine, Heidelberg, Germany).
Stable transfection
RKO and SW620 cells were transfected by using FuGENE HD transfection reagent (Roche Diagnostics Corporation, IN, USA) according to the manufacturer's instructions. To obtain Livin-overexpressing (OE) cells with stable transfection of expression plasmid and the control plasmid (empty vector, EV), cells were selected by Geneticin (400 μg/ml for RKO cells, 800 μg/ml for SW620 cells) for 2 weeks (starting at 24 h after transfection) and maintained in culture medium supplemented with Geneticin (200 μl/ml for RKO cells, 400 μg/ml for SW620 cells).
Western blot
The cells were lysed in RIPA buffer (150 mM NaCl, 2 % Triton, 0.1 % SDS, 50 mM Tris pH 8.0) containing 1 % Protease Inhibitor Cocktail (Sigma) after transfection. Protein concentrations were determined by BCA Protein Assay (Thermo Fisher, Woburn, MA, USA). Proteins were resolved by electrophoresis on TGX precast 10 % polyacrylamide gels (Bio-Rad, Hercules, CA, USA) and electroblotted to polyvinylidene difluoride membranes (GE Healthcare, Piscataway, NJ, USA) and then incubated with block solution (5 % nonfat milk, or 5 % BSA, 0.1 % Tween 20, in tris-buffered saline (TBS). Membranes were incubated with appropriate primary antibodies and then with secondary Horseradish Peroxidase (HRP)-conjugated antibodies (DakoCytomation, Glostrup, Denmark). Signals were detected by exposure to ECL Hyperfilms (GE Healthcare) after treatment with ECL Plus Western Blot Detection System (GE Healthcare). In some experiments, membranes were stripped with Restore™ Western Blot Stripping Buffer (Thermo Fisher) and reprobed.
The primary antibodies used were: Livin (goat polyclonal, 1: 3,000) from R&D Systems, Minneapolis, MN, USA; mTOR (rabbit polyclonal, 1: 1,500), phosphorylated (Ser 2481) mTOR (rabbit polyclonal, 1:1,500), BCL-2 (rabbit polyclonal, 1: 600), β-actin (rabbit monoclonal, 1: 10,000), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (rabbit monoclonal, 1: 10,000) from Cell Signaling Technology, Danvers, MA, USA; p-53 (mouse monoclonal, 1: 1,200), Ki-67 (rabbit monoclonal, 1: 200) from AbCam, Cambridge, UK; and Survivin (mouse monoclonal, 1: 800), BAX (rabbit polyclonal, 1: 500), and Bcl-XL (mouse monoclonal, 1: 600) from Santa Cruz, Santa Cruz, CA, USA.
WST-1 assay
Survival of cells after treatment was quantified by WST-1 assay (Roche) according to the manufacturer's instructions. Briefly, cells were seeded in 96-well tissue culture plate, in 100 μl culture medium. Ten microliters of WST-1 assay solution was added to each well and the cells were further incubated at 37°C for 2-3 h. The absorbance was measured at a wavelength of 450 nm on a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA, USA). Untreated cells served as the indicator of 100 % cell viability.
RNA interference (RNAi) knockdown Cells were transfected with either Dharmacon Non-Targeting scramble siRNA or ON-TARGETplus® SMARTpool siRNA against Livin (L-004391-00-5551, Thermo Fisher) by using DharmaFect 2 transfection reagent (Dharmacon) according to the manufacturer' instructions. The transfection mixture consisted of antibiotic-free culture medium and 100 nM siRNA.
DEVDase activity
The assay was performed on a VersaMax plate reader coupled with SoftMax software (Molecular Devices) operating in the endpoint or kinetic mode at 37°C. DEVDase activity was determined by using colorimetric pNA substrates (maximal absorbance at 405 nm). Assay buffer was 50 mM Tris, pH 7.4; 0.3 % NP-40, and 10 mM dithiothreitol. Data were recorded every 30 min for various periods of time as appropriate for each assay.
Immunocytochemistry
Cells were fixed in 4 % paraformaldehyde and permeabilized with 0.1 % Triton X-100 and incubated overnight at 4°C with antihuman cleaved caspase-3 antibody (rabbit polyclonal, 1: 200, Cell Signaling Technology), anti-Livin antibody (1: 100, R&D Systems). EnVision System (Dako) was used for staining with 3-diaminobenzidine (DAB) as chromogen and hematoxylin as counterstain.
Real-time PCR mRNA was extracted from cells using TuboCapture mRNA Preparation Kit (Qiagen, Hilden, Germany), followed by reverse transcription with a High Capacity cDNA Synthesis Kit (Applied Biosystems, Foster City, CA, USA) according the manufacturer's instruction. Real-time PCR reaction was performed on the ABI Prism 7500HT or 7900HT Sequence Detection System (Applied Biosystems) using the comparative threshold cycle (Ct) method (ΔΔCt). The PCR master mix was set up with TaqMan Fast Universal PCR Master Mix (Applied Biosystems).
Primers and probes were TaqMan® Gene Expression Assay for Livin and β-actin mRNA (Applied Biosystems).
Colony-forming assay
Log-phase cells were seeded in triplicate in the six-well plates with 2 ml complete media (500 cells/well) and incubated at 37°C in a humidified incubator. Plates were initially examined by light microscope to confirm that only single cells without clumps had been plated. Seven to ten days after plating, the colonies were fixed with 4 % formaldehyde and stained with 5 % Giemsa. Colonies were visualized with an Olympus IX51 microscope (Olympus, Japan). The colonies containing more than 50 cells were counted.
Statistic analysis
To evaluate statistical significance, the Student's t test was performed. The statistic analysis was performed by a statistician blinded to the experiment. Results are given as means ± standard error. All p values below 0.05 were considered significant.
Results
Responses to cisplatin of different colon cell lines
To test the effects of cisplatin, we used a panel of colon cancer cell lines including HCT116, RKO, KM12C, and SW620 with different concentrations of cisplatin (10 and 20 μg/ml) at 24 and 48 h post-treatment. The viable cells were determined by trypan blue exclusion, and cell numbers were analyzed on a Countess automatic cell counter (Sigma). The results showed these cells had different responses to cisplatin (Online Resource 1a). Treatment of RKO and KM12C cells resulted in significant reduction of cell survival. SW620 cells were more resistant to cisplatin because the survival changed only a little after drug addition. Also, HCT116 cells showed an intermediate response to cisplatin.
To further confirm these results, we used the WST-1 reagent to assay for the cell viability (Fig. 1a) . Increasing concentration of cisplatin (1, 5, 10, 20 , and 40 μg/ml) led to decreased cell viability in all cells tested. Again, the results showed RKO and KM12C cells were more sensitive, while SW620 and HCT116 cells were more resistant.
Finally, we determined the cisplatin sensitivity of colon cancer cells by using clonogeneity assay. From the results (Online Resource 1b), we could observe a significant decrease in colony number after addition of cisplatin in RKO and KM12C cells, but this was not the case for SW620 and HCT116 cells. Results of colony number and the survival fraction confirmed the observation (Fig. 1b, Online Resource 1c). From these results, we could conclude RKO and KM12C cells were the most sensitive to cisplatin treatment, followed by HCT116 cells, while the SW620 cells remained the most resistant cells. Fig. 1 Different responses to cisplatin in colon cancer cells were related to apoptosis. a Colon cancer cells (HCT116, RKO, KM12C, and SW620) were treated with cisplatin at an increasing concentration (1, 5, 10, and 20 μg/ml) for 24 h and then subjected to WST-1 agent assay. The cell survival was expressed relative to those without cisplatin treatment that was defined as 100 %. b The cells were treated with or without cisplatin and the survival fraction was calculated as: colony number/500 (total cell number seeded)×100 %. c Colon cancer cells were treated with increasing concentration of cisplatin (1, 5, 10, and 20 μg/ ml) for 24 h and were harvested and lysed as described in "Materials and methods". The lysates were detected for caspase-3 activity in the endpoint mode at 12 h after incubation. d Immunocytochemistry with a monoclonal antibody specific for the activated caspase-3 was shown (arrow indicated the activated caspase-3 in RKO and SW620 cells undergoing apoptosis after cisplatin treatment). The inhibitor for DEVDase z-DEVDfmk reversed partially the cytotoxicity induced by cisplatin for RKO and SW620 cells (E, p values: *100.010, *200.068, *3< 0.001, *4<0.001, *500.060, *600.019, *700.043, *80 0.416). d ×400 Cisplatin-induced cell death was related to cell apoptosis We assayed for caspase-3 activation that is considered as a critical biochemical event in apoptosis cascade [22, 23] . We could observe a dose-dependent increase of caspase-3 activity in cisplatin-treated RKO cells (Fig. 1c) . The increase of caspase-3 activity was correlated to prolonged incubation time in the kinetic mode. The same increase could be observed in cisplatin-treated SW620 cells. In this cell line, the caspase-3 activity was lower than that in RKO cells that was in good agreement of lower sensitivity of SW620 cells to cisplatin. These results remained till 12 h postincubation in the endpoint mode (Online Resource 2). Similar results were also observed for cisplain-treated HCT116 cells, but not for KM12C cells. These results remained constant in our following repeats (data not shown). KM12C cells seemed to have unique biochemical signaling independent of caspase-3 activation. The activation of caspase-3 was further confirmed by the immunohistochemical (IHC) staining by using a monoclonal antibody specific for activated caspase-3 (Fig. 1d) . Strong cytoplasmic staining could be observed after cisplatin treatment and was always accompanied by shrunk cell size that is a typical manifestation of cell apoptosis. Finally, we pretreated colon cancer cells with a caspase-3 inhibitor zDEVDfmk and found this inhibitor could salvage RKO and SW620 cells from cisplatininduced cell toxicity (Fig. 1e) . Different sensitivity to cisplatin was related to expression level of antiapoptotic factor Livin IAP members including Livin have been implicated in chemotherapy resistance in tumor cells [1, 4] . Here, we tested the relative expression level of Livin in these colon cells by Western blot (Fig. 2a) . In these cell lines, Livin expression level was highest in SW620 cells, followed by HCT116, RKO, and KM12C cells in order. The results were confirmed by real-time PCR as well (Fig. 2b) . That seemed to be a relationship between expression of Livin and intrinsic resistance to cisplatin. The higher expression level led to higher resistance and vice versa.
To further explore the relationship between Livin expression and cisplatin resistance, we treated colon cancer cells with increasing concentrations of cisplatin (10 and 20 μg/ ml) and determined the expression of Livin before and after cisplatin treatment (Fig. 2c) . We found expression of Livin increased with increasing dose of cisplatin in SW620, HCT116, and KM12C cells. However, in RKO cells that are among the most sensitive cells, the expression hardly changed. We also checked the expression of a panel of apoptosis-related factors such as Bcl-2, Bcl-XL, P53, Survivin, and Bax and found most of them remained constant except for P53 which expression increased with cisplatin treatment. Of note, HCT116 and RKO cells have wild type P53, while the others are with mutated P53. The interpretation of the observed increase of P53 should be done with caution and no conclusion was drawn. Cisplatin treatment did not change the subcellular localization of Livin A previous report indicated that Livin had both antiand proapoptotic function, which was determined by its different subcellular localization [24] . So we wanted to test the subcellular localization of Livin following cisplatin treatment. The subcellular localization of Livin was detected by immunocytochemistry staining both before and after cisplatin treatment. The expression of Livin was mainly restricted to cytoplasm and the distribution pattern remained the same before and after cisplatin treatment (Fig. 3a) . To further confirm these results, a cytoplasm and nucleus fractionation was performed (Fig. 3b) . Enrichment of Ki67/MIB-1 in the nucleus fraction and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the cytoplasmic fraction indicated the successful separation, and Livin was mainly restricted to the cytoplasmic fraction. These results showed cisplatin treatment did not change the cytoplasmic localization of Livin nor its antiapoptotic properties per se.
Cisplatin-induced Livin expression was related to activated mTOR pathway
We pretreated SW620 cells with a proteosome inhibitor MG132 and found there was actually no effect on Livin expression, either at the concentration of 20 or 40 μM. Nor did it abrogate cisplatin-induced Livin expression (Fig. 4a) . At these concentrations, there was already significant synergistic cytotoxicity with cisplatin (Fig. 4b) . We propose ubiquitin-proteosome pathway might be not so important at least for this cell line under this situation. Next, we used a protein synthesis inhibitor actinomycin D to treat the cells and found this reagent could drastically decrease the Livin expression level (Fig. 4c) . Interestingly, this inhibition could be reversed by adding cisplatin. We also used real-time PCR to determine the Livin mRNA, and the mRNA level also increased after cisplatin treatment (Fig. 4d) . These data provided clues cisplatin might induce Livin expression at the transcription or translation level. There was a report showing the regulation of Livin might be related to the mTOR pathway [25] . Therefore, we detected the activation of mTOR pathway by Western blot (Fig. 4e) . Activated mTOR pathway as shown by elevated phosphorylated AKT (p-AKT), phosphorylated mTOR (p-mTOR), phosphorylated S6K (p-S6K), and phosphorylated 4E-BP1 (p-4E-BP1) could be observed alongside an increased expression of Livin after cisplatin treatment in a dose-dependent fashion. The total amount of mTOR, S6K, and 4E-BP1 remained unchanged, although there was a slight decrease for total AKT and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). To further confirm if cisplatin-induced Livin expression was related to the mTOR pathway activation, we used a PI3K-mTOR inhibitor LY294002 to inhibit the activation of mTOR and found this inhibitor could abrogate the Livin upregulation induced by cisplatin (Fig. 4f) .
Overexpression of Livin led to cisplatin resistance Our next step was to confirm higher expression of Livin could make cells more resistant to cisplatin. We made stable transfectants of Livin overexpression (OE) from parental RKO and SW620 cells, and the transfectants were confirmed by Western blot (Fig. 5a ) and real-time PCR (Fig. 5b) . In the following studies, both overexpression transfectants showed higher cell viability to cisplatin than transfectants of EV (Fig. 5c) . Because it was proposed that Livin could inhibit apoptosis by binding and suppressing downstream caspases [3, 4] , in an attempt to explore the probable mechanism, we assayed the caspase-3 activity of the Livin overexpression transfectants with or without cisplatin treatment (Fig. 5d) . Fewer activities were observed from RKO.OE cells both in the presence or absence of cisplatin, compared with RKO.EV cells. For SW620.OE Fig. 3 The subcellular localization of Livin did not change after cisplatin treatment. a The subcellular localization of Livin in RKO and SW620 cells was detected by immunocytochemistry both before and after cisplatin treatment. b Nuclear/cytoplasmic fractionation was performed and Livin was found to be enriched in the cytoplasmic fraction both before and after cisplatin treatment. a (×400) cells, the caspase-3 activity increased less than two times, while it increased more than three times in SW620.EV cells. To this end, we also tested the impact of Livin expression on the sensitivity to oxaliplatin that is used for colon cancers. Similarly, we found overexpression of Livin rendered HCT-116 cells resistant to oxaliplatin (Online Resource 3).
Knockdown of Livin rendered cells more sensitive to cisplatin
Our data showed ectopic expression of Livin led to higher cisplatin resistance. In order to further confirm these results, we performed knockdown of Livin in RKO and SW620 cells by using siRNA. The knockdown was confirmed by our Western blot (Fig. 6a) and real-time PCR results (Fig. 6b) . Fig. 4 The upregulation of Livin by cisplatin treatment was related to mTOR pathway activation in colon cancer cells. a SW620 cells were treated with a proteosome inhibitor MG132 in the presence or absence of cisplatin. The expression of Livin was detected by Western blot. b At the concentration of 20 μM that we used in the experiment, MG132 significantly enhanced the cytotoxicity of cisplatin. c The inhibitor for RNA synthesis, actinomycin D, severely reduced the expression of Livin protein in a timedependent manner while coincubation with cisplatin could restore the expression of Livin. d The increase of Livin mRNA could be detected by real-time PCR after cisplatin treatment. e Cisplatin treatment led to increased phosphorylation of mTOR, S6K, Akt, and 4E-BP1 along the mTOR pathway, together with an upregulation of Livin. β-Actin was loaded as an internal control. f Treatment with the PI3K-mTOR inhibitor LY294002 could reduce the activation of mTOR and upregulation of Livin After knockdown of Livin, the cells showed less survival following cisplatin compared with scramble nontargeting siRNA-treated ones (Fig. 6c) . More importantly, cells with Livin knockdown have reduced colony formation capacity compared with scramble siRNA-treated counterparts (Fig. 6d) . The colony formation ability emphasizes the longterm survival capability and resembles the clinical settings to a greater extent than WST assay.
Discussion
Livin has been considered as a critical factor contributing to progression, poor prognosis, and therapeutic resistance in various types of tumors. Due to its distinctive enrichment in tumors but none or low expression in normal tissue, Livin has been proposed as a potential therapeutic target [19] . Several reports helped to expand its expression profile to variant tumors such as melanoma, leukemias, bladder, breast, cervical, nasopharyngeal, and lung cancer [5] [6] [7] [8] . However, there are only limited reports regarding its expression in Colorectal cancer (CRC) except some preliminary studies [17] [18] [19] [20] [21] . Previously, Livin expression was described in only three colon cancer cell lines (LoVo, HCT-8, and SW620). Here, we detected Livin expression in all seven colon cancer cell lines by Western blot (HCT116, RKO, KM12C, KM12L4A, KM12SM, SW480, and SW620, Online resource 4). The extensive expression of Livin in colon cancer cells implied Livin may be of importance in Colorectal cancer (CRC).
At the time of preparing this manuscript, other reports were published on similar topics [19, 20] . However, these studies were performed in separate colon cell lines and none of the cells used in our study was covered in these reports. Besides, platinum remains the mainstay of the chemotherapeutics. No experiments were performed to test the relationship between platinum sensitivity and Livin expression that the current study was intended to study. Therefore, the current study differed from previous reports. Platinum remains the mainstay therapeutic reagent for most of the solid tumors. In the current study, we determined the sensitivity to cisplatin of four colon cancer lines by using different methods. We concluded RKO and KM12C cells were the most sensitive, followed by HCT116 cells, while the SW620 cells remained as the most resistant ones. We also determined the type of cell death induced by cisplatin was related to apoptosis, except in KM12C cells where other mechanisms may be involved as well. Of note, other reports also indicated KM12C cells had a distinctive type of cell death beyond apoptosis [26] . The intriguing findings that different Livin expression levels were highly correlated to cisplatin resistance led us to suppose that Livin may play a role in mediating cisplatin resistance. Our next experiments showed that the expression of Livin increased when cells were treated with increasing doses of cisplatin. This may provide further evidence to support our hypothesis that Livin contributed to cisplatin resistance. We transfected Livin into RKO and SW620 cells and found the overexpressed Livin conferred the cells with resistance to cisplatin compared with the vector-transfected ones. Finally, we knocked down the endogenous Livin by siRNA and then the cells became more vulnerable to cisplatin. These data indicate that Livin might be a critical factor for cisplatin resistance for colon cancer cells.
Controversies remain regarding the mechanism by which Livin inhibits apoptosis. Initially, it was thought Livin could bind and suppress the downstream effector caspase-3, or caspase-9, which was a canonical mechanism used by other IAPs such as XIAP [3] . However, later experiments failed to prove this notion. Vucic et al. reported Livin could merely weakly inhibit caspase-9 activity with inhibition constant Ki approximately 3-5 μM. Also, it was argued that Livin might regulate apoptosis by sequestering SMAC from XIAP [27] . In our study, we found Livin overexpression led to resistance to cisplatin together with reduced caspase-3 activity. Our data indicated cisplatin resistance mediated by Livin might be involved with caspase inhibition by Livin, but the question of whether caspase-3 was inhibited by Livin directly or indirectly is awaiting further studies.
The mTOR protein kinase in eukaryotic cells has emerged as a critical growth control node, receiving stimulatory signals from PI3K and ras as well as nutrient input [28] . mTOR signaling pathway couples nutrient and energy to the execution of cell growth and division [29] . mTOR kinase can regulate the downstream kinases such as S6K, Akt, and 4E-BP1 and control gene expression thereby. A previous study showed an increased Akt activity after treatment with cisplatin in colon cancer cells HT29 [30] . This report was in line with the current results. In our study, we also found a dramatic increase in the activity of mTOR pathway molecules such as mTOR, S6K, and 4E-BP1 when the colon cancer cells SW620 were treated with cisplatin. The activation of the mTOR pathway was linked to the induced Livin expression by cisplatin. These results led us to suspect the increased expression of Livin might be a downstream event of mTOR activation.
In the current study, we failed to show the regulation of Livin expression by ubiquitin-proteosome pathway in SW620 cells although there was a report where the redundancy of Livin was dependent on its degradation by proteosome [13] . Neither could we find this regulation in another colon cancer cell line HCT116 (data not shown). The mechanism behind this discrepancy between the report and our study remains elusive at present, but we speculated that this was partly attributed to the low expression level of Livin in colon cancer cells compared with HeLa cervical cancer cells or melanoma cells (data not shown). Livin may have a different regulation pattern in different types of cancers. We found that cisplatin induced Livin expression in most of the colon cancer cells and in an attempt to explore the possible mechanism, and the increase of Livin was at the transcription or translation level. Furthermore, we could detect an increase of Livin mRNA after cisplatin treatment. Also, the inhibition of PI3K-mTOR pathway could partially abrogate the increase of Livin expression. Taken together, we reasoned the increase of Livin by cisplatin may be at both transcription and translation levels.
In summary, we find a high prevalence of Livin expression in colon cancer cells and its expression is strongly related to the resistance to cisplatin. Livin expression increases following cisplatin treatment, and the regulation is enhanced from both transcription and translation levels. Forced overexpression of Livin increases the cisplatin resistance, while knockdown sensitizes cancer cells to cisplatin. Our study, along with others, highlighted the potential of Livin for cancer therapy in colon cancer.
